Antiviral efficacy of heparan sulfate and enoxaparin sodium against SARS‐CoV‐2
Archiv der Pharmazie · 2025
DOI: 10.1002/ardp.202400545 ↗Kurz gefasst
Fachartikel in der Zeitschrift Archiv der Pharmazie, 2025. Verfasst von Virginia Fuochi und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical and Biotechnological Sciences (Biometec), University of Catania, Catania, Italy. Hauptthemen laut MEDLINE: Enoxaparin, Heparan Sulfate, SARS-CoV-2, Antiviral Agents. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Techdow Pharma Italy S.r.l., NextGeneration EU-MUR PNRR Extended Partnership on Emerging Infectious Diseases.
Abstract (Originalsprache)
As the world transitions from the acute phase of the COVID‐19 pandemic caused by SARS‐CoV‐2, the scientific community continues to explore various therapeutic avenues to control its spread and mitigate its ongoing effects. Among the promising candidates are heparan sulfate (HS) and enoxaparin (EX), which have emerged as potential virus inhibitors. HS, a type of glycosaminoglycan, plays a prominent role in the attachment of the virus to host cells. At the same time, EX, a low‐molecular‐weight heparin, is being investigated for its ability to disrupt the interaction between the spike protein of SARS‐CoV‐2 and the ACE2 receptor in human cells. Understanding the mechanisms through which these substances operate could lay the foundation for new strategies in the ongoing management of COVID‐19. This study aimed to examine the details of SARS‐CoV‐2's entry mechanisms and the role of HS in this process. Furthermore, it examines EX's mechanism of action, highlighting how it potentially inhibits SARS‐CoV‐2. The interactions between HS and the virus, alongside in‐vitro and in‐silico inhibition studies with HS and EX, are critically analyzed to assess their antiviral efficacy. Additionally, the antiviral activity of sulfated polysaccharides and the potential therapeutic applications of these findings are discussed.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biomedical and Biotechnological Sciences (Biometec), University of Catania, Catania, Italy.
- Department of Drug and Health Sciences (DSFS), University of Catania, Catania, Italy.
Förderung
- Techdow Pharma Italy S.r.l.
- NextGeneration EU-MUR PNRR Extended Partnership on Emerging Infectious Diseases
Zitieren
APA
Fuochi, V., Furnari, S., Floresta, G., Patamia, V., Zagni, C., Drago, F., Rescifina, A., & Furneri, P. M. (2025). Antiviral efficacy of heparan sulfate and enoxaparin sodium against SARS‐CoV‐2. Archiv der Pharmazie. https://doi.org/10.1002/ardp.202400545
Vancouver
Fuochi V, Furnari S, Floresta G, Patamia V, Zagni C, Drago F, et al. Antiviral efficacy of heparan sulfate and enoxaparin sodium against SARS‐CoV‐2. Archiv der Pharmazie. 2025. doi:10.1002/ardp.202400545
BibTeX
@article{Fuochi2025,
author = {Fuochi, Virginia and Furnari, Salvatore and Floresta, Giuseppe and Patamia, Vincenzo and Zagni, Chiara and Drago, Filippo and Rescifina, Antonio and Furneri, Pio Maria},
title = {Antiviral efficacy of heparan sulfate and enoxaparin sodium against SARS‐CoV‐2},
journal = {Archiv der Pharmazie},
year = {2025},
doi = {10.1002/ardp.202400545}
}
EUVIMED